JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Home・Akcijų sąrašas・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

21.95 -2.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

21.69

Max

Pagrindiniai rodikliai
By Trading Economics
Pajamos	202M 274M
Pardavimai	5.4M 284M
P/E Sektoriaus vid.	9.696 67.147
Pelno marža	96.33
Darbuotojai	796
EBITDA	-21M 26M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+40.49% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-366M 3.8B
Ankstesnė atidarymo kaina	24.35
Ankstesnė uždarymo kaina	21.95

Naujienos nuotaikos

By Acuity

28%

72%

79 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bullish Evidence

14.845 / N/A Palaikymas ir pasipriešinimas

ACADIA Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-01 21:36; UTC

Įsigijimai, susijungimai, perėmimai

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

2026-05-01 20:40; UTC

Įsigijimai, susijungimai, perėmimai

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

2026-05-01 18:37; UTC

Pagrindinės rinkos jėgos

Senseonic Shares Slide on Underwritten Offering Price

2026-05-01 16:46; UTC

Pagrindinės rinkos jėgos

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

2026-05-01 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 20:42; UTC

Uždarbis

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

2026-05-01 19:33; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-01 19:33; UTC

Rinkos pokalbiai

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

2026-05-01 19:18; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

2026-05-01 19:13; UTC

Rinkos pokalbiai

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

2026-05-01 18:36; UTC

Uždarbis

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

2026-05-01 18:35; UTC

Uždarbis

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

2026-05-01 18:28; UTC

Uždarbis

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

2026-05-01 18:27; UTC

Rinkos pokalbiai

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

2026-05-01 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Barclays Completes Acquisition of Best Egg

2026-05-01 18:04; UTC

Uždarbis

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

2026-05-01 17:43; UTC

Rinkos pokalbiai

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

2026-05-01 17:37; UTC

Rinkos pokalbiai

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

2026-05-01 17:30; UTC

Rinkos pokalbiai

Uždarbis

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

2026-05-01 17:28; UTC

Rinkos pokalbiai

Uždarbis

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

2026-05-01 17:21; UTC

Rinkos pokalbiai

Uždarbis

Apple Seen Absorbing Higher Memory Costs -- Market Talk

2026-05-01 17:19; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

2026-05-01 16:38; UTC

Rinkos pokalbiai

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

2026-05-01 16:23; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

2026-05-01 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-05-01 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-05-01 16:15; UTC

Uždarbis

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

2026-05-01 16:11; UTC

Rinkos pokalbiai

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

2026-05-01 16:04; UTC

Uždarbis

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

ACADIA Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

40.49% į viršų

12 mėnesių prognozė

Vidutinis 31.54 USD 40.49%

Aukščiausias 40 USD

Žemiausias 23 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines ACADIA Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių ACADIA Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

14.845 / N/APalaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

79 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.